RxDoctor Payments Data

Daniel Chin, MD

Internal Medicine · Binghamton, NYNPI 1497072979

Payments from drug & device makers

$4,818in general payments, 2019–2025

Across 281 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$753
  • Pfizer$542
  • AstraZeneca$411
  • Viiv Healthcare Company$325
  • Novo Nordisk$218
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,806100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,818 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$9,144
Medicare patients
66
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin13$20,524
TrulicityDulaglutide15$19,251
EliquisApixaban17$15,813
JanuviaSitagliptin Phosphate14$6,725
Breo ElliptaFluticasone/Vilanterol11$6,011
Celecoxib14$4,361
Albuterol Sulfate HfaAlbuterol Sulfate49$1,857
Famotidine13$1,750
Desipramine Hcl16$1,345
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen29$920
Atorvastatin Calcium141$823
Gabapentin44$590
Pantoprazole Sodium72$548
Hydroxyzine Hcl14$522
Omeprazole57$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$155$20,52413 claims
Lilly USA, LLCTrulicity$38$19,25115 claims
PfizerEliquis$542$15,81317 claims
MerckJanuvia$79$6,72514 claims
GSKBreo Ellipta$753$6,01111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Binghamton

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →